Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy
Alemtuzumab is a pan-lymphocyte depleting anti-CD52 antibody, and is approved as an escalation therapy for patients with multiple sclerosis with active disease defined by clinical or imaging features. In phase 3 clinical trials, the drug was more effective than interferon beta-1a in reducing relapse...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Lancet
2017
|